Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $23.00 | Market Perform | Leerink Partners |
2/20/2024 | Hold → Reduce | HSBC Securities | |
1/3/2024 | $21.00 | Underweight | Barclays |
12/22/2023 | $27.00 | Hold | HSBC Securities |
10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
2/23/2023 | $45.00 | Buy | Loop Capital |
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of artificial intelligence technology’s potential. Building On Gains: The S&P 500 Index, a measure of broader market performance, has gained a robust 14.48% so far this year, and it is up 3.92% for the second quarter. The index last hit a record closing high (5,487.03) on June 18, and breached the 5,500 mark intraday on June 20. Since then, the broader gauge has been going about a consolidation move. The SPDR S&P 500 ETF Trust (NYSE:SPY), an exchange-traded fund that tracks the performance of th
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares tumbled 24.12% after the company reported mixed Q3 earnings and lowered 2024 guidance below consensus estimates. Analysts cut the price forecasts on the stock. Floor & Decor Holdings, Inc. (NYSE:FND) shares lost 13.41%, possibly in reaction to worse-than-expected May Pending Home Sales economic data. Moderna, Inc. (NASDAQ:MRNA) shares fell 11.76% after the company’s RSV vaccine showed 50% efficacy. Birkenstock Holding Plc (NYSE:BIRK) stock declined 10.86% after the company announced an offering of up to 14 million ordinary sh
The Federal Reserve's most closely monitored inflation measure — the Personal Consumption Expenditure price index — reached its lowest level since March 2021 in May, registering an annual rate of 2.6%, in line with economist expectations. The inflation figures released Friday indicate that price pressures are trending toward the Fed's 2% target, solidifying market expectations for interest rate cuts. September is now seen as the most likely month for the first rate cut, followed by another by the end of the year, and potentially three more next year, according to market prediction data. The first presidential debate concluded with a spike in Donald Trump's win probabilities to about 60
On Thursday, Walgreens Boots Alliance Inc (NASDAQ: WBA) reported third-quarter fiscal year 2024 sales of $36.35 billion, up 2.6% year over year (+2.5% on constant currency), beating the consensus of $36 billion. Walgreens Boots Alliance has cut its fiscal year 2024 adjusted EPS guidance to $2.80-$2.95, compared to prior guidance of $3.20-$3.35 and consensus of $3.22. As the earnings fell short of Wall Street estimates, the pharmacy chain revealed it would close a “significant” number of stores in the face of “headwinds.” The disappointing earnings report caused shares to tumble as much as 25%. Analyst reactions: Barclays maintains the Underweight rating and lowers the price ta
Barclays analyst Steve Valiquette maintains Walgreens Boots Alliance (NASDAQ:WBA) with a Underweight and lowers the price target from $15 to $11.
Truist Securities analyst David Macdonald maintains Walgreens Boots Alliance (NASDAQ:WBA) with a Hold and lowers the price target from $20 to $13.
Morgan Stanley analyst Erin Wright maintains Walgreens Boots Alliance (NASDAQ:WBA) with a Underweight and lowers the price target from $13 to $9.
Economists have broadly welcomed the latest key piece of inflation data, with the Personal Consumption Expenditure (PCE) price index — commonly referred to as the Fed’s favorite measure of inflation — dropping to a 2.6% year-on-year rate in May 2024, its lowest level since March 2021. This decline signals significant progress in the Federal Reserve’s efforts to bring inflation closer to its 2% target, opening the door for interest rate cuts by year-end. Following the release, the futures market currently predicts a 52 basis point reduction in the fed funds rate by December 2024, effectively pricing in two rate cuts, with a 68% probability that the first cut could happen as early as Se
B of A Securities analyst Allen Lutz reiterates Walgreens Boots Alliance (NASDAQ:WBA) with a Underperform and lowers the price target from $22 to $11.
Evercore ISI Group analyst Elizabeth Anderson maintains Walgreens Boots Alliance (NASDAQ:WBA) with a In-Line and lowers the price target from $17 to $10.
On Thursday, Walgreens Boots Alliance Inc (NASDAQ: WBA) reported third-quarter fiscal year 2024 sales of $36.35 billion, up 2.6% year over year (+2.5% on constant currency), beating the consensus of $36 billion.
Walgreens Boots Alliance has cut its fiscal year 2024 adjusted EPS guidance to $2.80-$2.95, compared to prior guidance of $3.20-$3.35 and consensus of $3.22.
As the earnings fell short of Wall Street estimates, the pharmacy chain revealed it would close a “significant” number of stores in the face of “headwinds.”
The disappointing earnings report caused shares to tumble as much as 25%.
Analyst reactions:
Barclays maintains the Underweight rating and lowers the price target from $15 to $11, stating Walgreens Boots Alliance cut its fiscal year 2024 EPS guidance on continued macro headwinds, which it expects to persist to fiscal year 2025.
BofA Securities reiterates the Underperform rating and lowers the price target to $11 from $22, citing headwinds that will persist/limited positive catalysts.
Evercore ISI maintains Walgreens Boots Alliance with an In-Line rating, lowering the price target from $17 to $10.
Price Action: WBA shares are down 0.90% at $12.08 at last check Friday.
Photo via Wikimedia Commons
Lowering Guidance in Continued Challenging Environment; Provides Strategic Update Third quarter financial highlights Third quarter earnings per share (EPS)* was $0.40 compared to earnings per share of $0.14 in the year-ago quarter which included a non-cash impairment of pharmacy license intangible assets in Boots UK Adjusted EPS** was $0.63, down 36.6 percent on a constant currency basis compared to the year-ago quarter, including a $0.24 impact from lower sale-leaseback gains, a challenging U.S. retail environment, and recent pharmacy industry trends Third quarter sales increased 2.6 percent year-over-year to $36.4 billion, up 2.5 percent on a constant currency basis Fiscal
The collaboration is the largest National HIV Testing Day event in the Nation Walgreens and Greater Than HIV, a public information initiative of KFF, are teaming up with health departments and community organizations to offer free rapid HIV testing in more than 550 Walgreens stores on June 27 in the largest coordinated National HIV Testing Day event. Additionally, to address the rising rates of other sexually transmitted diseases (STDs), free rapid syphilis and/or hepatitis C testing will also be offered by partners this year in many locations. "This unique public-private partnership brings free rapid HIV and STD testing directly to communities in a familiar setting and connects indiv
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal 2024 third quarter results at 7 a.m. ET on Thursday, June 27, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail
Walgreens continues to lower prices on over 1,300 products, and offers promotions to help consumers save Walgreens today introduced more opportunities for consumers to save throughout the season and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529305565/en/Walgreens to lower prices on over 1,300 products throughout the season and beyond. (Photo: Business Wire) The company also plans to introduce a series of promotional campaigns, including the return of Walgreens popular myW Days in mid-July. "Walgreens understands our customers are under financial strain and struggle to purchase everyday essentials. We continue
Walgreens will host its first community health fair at a store in San Juan on Saturday, June 8. As a trusted health and wellness destination in Puerto Rico, Walgreens is bringing the community together in San Juan by launching its first community health fair, "Walgreens en tu Comunidad," to offer health-related education, screenings and vaccinations. Services offered include blood pressure screenings, which according to the Centers for Disease Control and Prevention data, more than 40% of people in Puerto Rico surveyed have been told they have high blood pressure. The event will take place on Saturday, June 8 from 10 a.m. to 4 p.m. ET in the parking lot of the Walgreens store in Montehi
Walgreens Boots Alliance announces sale of Cencora, Inc. shares for proceeds of approximately $400 million from Cencora stock repurchase Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold shares of Cencora, Inc. (NYSE:COR) pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 13 percent to approximately 12 percent. Proceeds to
The healthcare company expands access by launching its brand of naloxone, a life-saving medication used to reverse the effects of an opioid overdose if used in time Walgreens today announced it is expanding access to an over the counter, life-saving medication with the launch of Walgreens Brand Naloxone HCI Nasal Spray. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515511221/en/Walgreens Brand Naloxone HCl Nasal Spray, 4mg now available in stores and online. (Photo: Business Wire) The product—which retails for $34.99, a lower price than the comparable national brand product at Walgreens stores, can reverse an overdose from
Joint collaborations bring Boehringer Ingelheim's Phase III clinical trial to communities through Walgreens pharmacy clinical trial centers and EmVenio's mobile research units, aimed at improving access to trials Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and research. This press release featur
Walgreens (NASDAQ:WBA): UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC., Plaintiff, v. STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M. SCHLICHTING, and JAMES A. SKINNER, Defendants, and WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation, Nominal Defendant. Case No. 23-cv-15654 SUMMARY NOTICE SUMMARY NOTICE OF PENDENCY AND PROPOSED SET
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on June 12, 2024, to stockholders of record as of May 21, 2024. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 366 straight quarters (91 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximatel
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Reporting)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
3 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
10-Q - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
13F-HR - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
10-Q - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
144 - Walgreens Boots Alliance, Inc. (0001618921) (Reporting)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
Lowering Guidance in Continued Challenging Environment; Provides Strategic Update Third quarter financial highlights Third quarter earnings per share (EPS)* was $0.40 compared to earnings per share of $0.14 in the year-ago quarter which included a non-cash impairment of pharmacy license intangible assets in Boots UK Adjusted EPS** was $0.63, down 36.6 percent on a constant currency basis compared to the year-ago quarter, including a $0.24 impact from lower sale-leaseback gains, a challenging U.S. retail environment, and recent pharmacy industry trends Third quarter sales increased 2.6 percent year-over-year to $36.4 billion, up 2.5 percent on a constant currency basis Fiscal
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal 2024 third quarter results at 7 a.m. ET on Thursday, June 27, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on June 12, 2024, to stockholders of record as of May 21, 2024. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 366 straight quarters (91 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximatel
Second quarter operational results in line with expectations, U.S. Healthcare achieved adjusted EBITDA profitability, narrowing full-year adjusted EPS guidance range Second quarter financial highlights Second quarter loss per share* was $6.85 compared to earnings per share of $0.81 in the year-ago quarter; Second quarter results included a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill Adjusted earnings per share (EPS)** increased 3.4 percent to $1.20, up 2.8 percent on a constant currency basis reflecting lower adjusted effective tax rate** and improved profitability in U.S. Healthcare Second quarter sales increased 6.3 percent year-over-year to
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal 2024 second quarter results at 7 a.m. ET on Thursday, March 28, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retai
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, a reduction of 48 percent from the previous quarter. The dividend is payable on March 12, 2024, to stockholders of record as of Feb. 20, 2024. Chief Executive Officer Tim Wentworth said: "Since the start of my tenure with WBA, we have been evaluating our options across our strategies and operations, including those related to our capital allocation. We have made the difficult decision to reduce our quarterly dividend payment to 25 cents per share, to strengthen our long-term balance sheet and cash position. This action reinforces our goal of in
Results In Line with Expectations; Executing in a Challenging Environment First quarter and recent financial highlights First quarter loss per share* was $0.08 compared to a loss per share of $4.31 in the year-ago quarter; first quarter results included $278 million after-tax charge for fair value adjustments on variable prepaid forward derivatives related to the monetization of Cencora shares Adjusted earnings per share (EPS**) decreased 43.1 percent to $0.66, down 43.7 percent on a constant currency basis reflecting challenging retail market trends in the U.S. and a 21 percentage point headwind from a higher tax rate First quarter sales increased 10.0 percent year-over-year to
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal 2024 first quarter results at 7 a.m. ET on Thursday, January 4, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. The replay will also be available from approximately 11:30 a.m. ET, Jan. 4, 2024 through Jan. 11, 2024, by calling + 1 800 770 2030 within the U.S. and Canada, or + 1 647 362 9199 internationally, using replay code 8277955. About Walgreens Boots Alliance Walgreens Bo
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter. The dividend is payable on Dec. 12, 2023, to stockholders of record as of Nov. 14, 2023. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 364 straight quarters (91 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximate
Company Appoints Tim Wentworth as Chief Executive Officer Fourth quarter and fiscal year financial highlights Fourth quarter loss per share* was $0.21 versus $0.48 in the year-ago quarter; adjusted earnings per share (EPS*) was $0.67, down 18.0 percent on a constant currency basis, reflecting a 23.5 percent headwind from significantly lower COVID-19 vaccine and testing volumes Fiscal 2023 loss per share was $3.57 compared with $5.01 earnings per share in the year-ago period; adjusted EPS was $3.98, down 20.3 percent on a constant currency basis, impacted by a 20.7 percent headwind from significantly lower COVID-19 vaccine and testing volumes Fourth quarter sales increased 9.2 per
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation's medically underserved populations, and Foundation for Sarcoidosis Research (FSR), the leading international sarcoidosis organization, are proud to announce its renewed partnership to raise education and awareness about sarcoidosis and the importance of spring vaccinations with all Alabama-based Walgreens stores. As part of April's Sarcoidosis Awareness Month from now through April 30th, all Walgree
Eligible Medicare Advantage members can now use their benefits to purchase approximately 1,700 items digitally for shipping, pickup or same-day delivery Today, Walgreens announced it is the first community pharmacy to accept a broad array of Medicare Advantage supplemental benefits online, through Walgreens.com and the Walgreens app. Eligible members can now shop from a catalog of approximately 1,700 Shop Eligible Products on Walgreens digital channels. Consumers have been able to shop using their Medicare Advantage supplemental benefits in stores since 2019 and this brings even greater convenience with new digital shopping solutions regardless of payment method. This press release featu
Appointment completes CEO Tim Wentworth's Executive Committee Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today named Lanesha Minnix the company's executive vice president (EVP) and global chief legal officer. Minnix, most recently EVP, general counsel and corporate secretary for Ecolab, Inc., will assume her new role with WBA on April 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226589815/en/Lanesha Minnix named global chief legal officer, Walgreens Boots Alliance (Photo: Business Wire) Minnix, who will report to WBA CEO Tim Wentworth and serve on his Executive Committee, will oversee the company's global legal, comp
NEW YORK, Feb. 20, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average (DJIA) and Dow Jones Transportation Average (DJTA) effective prior to the open of trading on Monday, February 26: Amazon.com Inc. (NASD:AMZN) will replace Walgreens Boots Alliance Inc. (NASD:WBA) in the Dow Jones Industrial Average. Reflecting the evolving nature of the American economy, this change will increase consumer retail exposure as well as other business areas in the DJIA. The index change was prompted by DJIA constituent Walmart Inc.'s (NYSE:WMT) decision to split its stock 3:1, which will reduce Walmart's index weight due to the price weighted construc
Brings deep healthcare and extensive finance experience Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the election of Robert L. (Robbie) Huffines to the company's board of directors at its 2024 Annual Meeting of Stockholders. He joins the board as an independent director and will serve on the board's Finance and Technology Committee. Huffines currently serves as Global Chairman of Investment Banking at J.P. Morgan Chase & Co., where he has guided healthcare companies for more than 30 years on strategy, mergers and acquisitions, divestitures and financing. He expects to retire from J.P. Morgan Chase early this year. Huffines brings experience across many healthcare vertic
Take five minutes with Walgreens this holiday season to explore trending, budget-friendly gifts and essentials Walgreens has everything you need to keep things merry and bright – with convenient in-person and online shopping options to save the day, especially when you need help last-minute. According to a new Walgreens U.S. gift giving trend survey, 83% of Americans found themselves getting a gift for someone at the very last minute—a trend even more common among Gen Z (90%) and parents (92%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213156937/en/Take five minutes with Walgreens this holiday season. (Photo: Business
Mr. Wentworth brings nearly three decades of healthcare leadership experience to WBA Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the appointment of Tim Wentworth as the company's new Chief Executive Officer, effective on October 23. Mr. Wentworth will also join the WBA Board of Directors upon assuming the role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011544834/en/Tim Wentworth named Walgreens Boots Alliance CEO (Photo: Business Wire) Most recently, as founding CEO of Evernorth, Cigna's health services organization that partners with health plans, employers and government organizations, Mr. Wentworth b
Rosalind Brewer Steps Down as CEO and Member of the Board Ginger Graham, Current Lead Independent Director, Appointed Interim CEO Search Process to Identify a Permanent CEO Is Underway Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms. Brewer will step down as the Company's Chief Executive Officer (CEO) and as a member of the Board, as of August 31, 2023. The Board has appointed Ginger Graham, current Lead Independent Director of WBA, as the Company's interim CEO. Ms. Brewer has agreed to continue to advise WBA while the Company conducts a search for a permanent CEO. Stefano Pessina, Executive Cha
James Kehoe to depart as Global CFO; Manmohan Mahajan appointed Interim Global CFO Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the departure of James Kehoe, Executive Vice President and Global Chief Financial Officer. Mr. Kehoe will leave WBA in mid-August to pursue an opportunity in the technology sector. Manmohan Mahajan, Senior Vice President, Global Controller, has been named Interim Global Chief Financial Officer while the company conducts a search to fill the role with a leader who not only brings deep financial acumen to WBA, but also healthcare experience. Chief Executive Officer, Rosalind Brewer, acknowledged Kehoe's impact on the company saying, "James has been
Polen's dedication to redefining the future of healthcare and MedTech development bolsters WBA board as company accelerates healthcare transformation Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the appointment of Tom Polen to the company's board of directors. Polen brings more than 25 years of experience advancing healthcare solutions and technologies to the WBA board, as the company continues to accelerate its healthcare transformation and growth strategy. He will serve on the board's Finance and Technology Committee. Polen is the chairman, CEO and president of BD (Becton, Dickinson and Company), one of the world's largest medical technology companies. Prior to his curr
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Barclays initiated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $21.00
HSBC Securities initiated coverage of Walgreens Boots Alliance with a rating of Hold and set a new price target of $27.00
JP Morgan upgraded Walgreens Boots Alliance from Neutral to Overweight and set a new price target of $30.00 from $27.00 previously
Morgan Stanley reiterated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $27.00 from $37.00 previously
Deutsche Bank downgraded Walgreens Boots Alliance from Buy to Hold and set a new price target of $34.00 from $46.00 previously
Loop Capital initiated coverage of Walgreens Boots Alliance with a rating of Buy and set a new price target of $45.00
Morgan Stanley resumed coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $39.00
Cowen upgraded Walgreens Boots Alliance from Market Perform to Outperform and set a new price target of $54.00 from $43.00 previously